| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 6 | 2024 | 765 | 1.400 |
Why?
|
| Lymphocytosis | 3 | 2021 | 57 | 1.380 |
Why?
|
| Influenza Vaccines | 4 | 2024 | 498 | 1.140 |
Why?
|
| Vaccination | 10 | 2020 | 1166 | 1.090 |
Why?
|
| Immunity, Humoral | 3 | 2021 | 88 | 1.010 |
Why?
|
| Immunization | 2 | 2018 | 399 | 0.940 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2024 | 95 | 0.830 |
Why?
|
| Vaccines | 6 | 2020 | 399 | 0.820 |
Why?
|
| Vaccination Coverage | 2 | 2018 | 36 | 0.780 |
Why?
|
| Adenosine Monophosphate | 3 | 2021 | 76 | 0.730 |
Why?
|
| Alanine | 3 | 2021 | 247 | 0.700 |
Why?
|
| Immunocompetence | 1 | 2020 | 73 | 0.690 |
Why?
|
| Contraindications | 1 | 2020 | 154 | 0.680 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 191 | 0.630 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2021 | 2486 | 0.580 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2017 | 49 | 0.570 |
Why?
|
| Antibodies, Viral | 6 | 2024 | 1301 | 0.560 |
Why?
|
| Nasopharynx | 1 | 2017 | 117 | 0.560 |
Why?
|
| Antiviral Agents | 4 | 2021 | 1253 | 0.540 |
Why?
|
| Skull Base | 1 | 2017 | 225 | 0.520 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 166 | 0.520 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 252 | 0.500 |
Why?
|
| Measles | 2 | 2016 | 38 | 0.500 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2021 | 12 | 0.490 |
Why?
|
| Immunization, Passive | 1 | 2015 | 188 | 0.480 |
Why?
|
| Mumps | 1 | 2014 | 12 | 0.480 |
Why?
|
| Health Personnel | 3 | 2018 | 652 | 0.470 |
Why?
|
| HIV-1 | 2 | 2014 | 639 | 0.470 |
Why?
|
| Osteomyelitis | 1 | 2017 | 258 | 0.470 |
Why?
|
| Education, Medical | 1 | 2018 | 344 | 0.440 |
Why?
|
| Global Health | 1 | 2018 | 692 | 0.430 |
Why?
|
| Latent Tuberculosis | 2 | 2018 | 86 | 0.430 |
Why?
|
| HIV Infections | 2 | 2017 | 2154 | 0.420 |
Why?
|
| Hepatitis B Vaccines | 1 | 2012 | 50 | 0.410 |
Why?
|
| Infection Control | 1 | 2014 | 278 | 0.400 |
Why?
|
| Travel | 2 | 2014 | 203 | 0.390 |
Why?
|
| Disease Outbreaks | 1 | 2014 | 405 | 0.390 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 518 | 0.370 |
Why?
|
| Hepatitis B virus | 1 | 2012 | 225 | 0.370 |
Why?
|
| Hemagglutination Inhibition Tests | 3 | 2024 | 121 | 0.370 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 625 | 0.350 |
Why?
|
| Hepatitis B | 1 | 2012 | 275 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 600 | 0.340 |
Why?
|
| Paratyphoid Fever | 1 | 2009 | 1 | 0.330 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2009 | 6 | 0.330 |
Why?
|
| Viral Vaccines | 1 | 2022 | 363 | 0.330 |
Why?
|
| Typhoid Fever | 1 | 2009 | 22 | 0.320 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2021 | 136 | 0.300 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 1059 | 0.290 |
Why?
|
| Immunity, Cellular | 2 | 2021 | 440 | 0.290 |
Why?
|
| Cystitis | 1 | 2008 | 109 | 0.280 |
Why?
|
| HIV | 1 | 2008 | 236 | 0.270 |
Why?
|
| Internship and Residency | 1 | 2018 | 1452 | 0.270 |
Why?
|
| Adult | 23 | 2024 | 82040 | 0.270 |
Why?
|
| Parenteral Nutrition, Home | 2 | 2016 | 11 | 0.270 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2021 | 214 | 0.270 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 368 | 0.260 |
Why?
|
| Humans | 39 | 2024 | 270740 | 0.250 |
Why?
|
| Aged | 18 | 2024 | 73333 | 0.250 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 496 | 0.240 |
Why?
|
| Interferon-gamma Release Tests | 2 | 2018 | 89 | 0.240 |
Why?
|
| Double-Blind Method | 5 | 2021 | 2580 | 0.240 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 18 | 0.230 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 1 | 2024 | 28 | 0.230 |
Why?
|
| Male | 25 | 2024 | 128315 | 0.230 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2014 | 34 | 0.220 |
Why?
|
| AIDS Vaccines | 1 | 2014 | 66 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2021 | 2828 | 0.220 |
Why?
|
| Single-Blind Method | 3 | 2021 | 413 | 0.220 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.210 |
Why?
|
| Catheter-Related Infections | 2 | 2016 | 274 | 0.210 |
Why?
|
| Drug Carriers | 1 | 2014 | 336 | 0.200 |
Why?
|
| Interferon beta-1a | 1 | 2021 | 23 | 0.200 |
Why?
|
| Middle Aged | 20 | 2024 | 90352 | 0.200 |
Why?
|
| Herpes Zoster | 1 | 2021 | 53 | 0.190 |
Why?
|
| Immunization, Secondary | 2 | 2022 | 117 | 0.190 |
Why?
|
| Age Factors | 3 | 2020 | 5457 | 0.190 |
Why?
|
| Patient Acuity | 2 | 2021 | 78 | 0.190 |
Why?
|
| Female | 22 | 2024 | 148940 | 0.190 |
Why?
|
| Incidence | 5 | 2021 | 5824 | 0.180 |
Why?
|
| Azetidines | 1 | 2020 | 95 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2023 | 209 | 0.180 |
Why?
|
| Bacteremia | 2 | 2016 | 721 | 0.170 |
Why?
|
| Young Adult | 8 | 2021 | 22251 | 0.170 |
Why?
|
| Placebos | 2 | 2015 | 442 | 0.170 |
Why?
|
| Purines | 1 | 2020 | 271 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 212 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 2 | 2024 | 695 | 0.160 |
Why?
|
| Influenza A virus | 1 | 2019 | 166 | 0.160 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 719 | 0.150 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 1424 | 0.150 |
Why?
|
| Adaptive Immunity | 2 | 2017 | 151 | 0.150 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2017 | 37 | 0.150 |
Why?
|
| Herpesvirus 3, Human | 1 | 2017 | 45 | 0.140 |
Why?
|
| Myeloblastin | 1 | 2017 | 65 | 0.140 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 372 | 0.140 |
Why?
|
| Health Resources | 1 | 2018 | 171 | 0.140 |
Why?
|
| Seasons | 1 | 2018 | 337 | 0.140 |
Why?
|
| Muscle Weakness | 1 | 2017 | 111 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 146 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 159 | 0.130 |
Why?
|
| Adolescent | 7 | 2021 | 32767 | 0.130 |
Why?
|
| Measles Vaccine | 1 | 2015 | 12 | 0.130 |
Why?
|
| Immunogenetics | 1 | 2015 | 18 | 0.130 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2020 | 131 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2021 | 13414 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 1051 | 0.120 |
Why?
|
| Influenza B virus | 1 | 2015 | 97 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 287 | 0.120 |
Why?
|
| Systems Biology | 1 | 2015 | 115 | 0.120 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2014 | 15 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 30998 | 0.120 |
Why?
|
| Communicable Disease Control | 1 | 2016 | 174 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2018 | 821 | 0.110 |
Why?
|
| Diarrhea | 1 | 2017 | 716 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2017 | 602 | 0.110 |
Why?
|
| Georgia (Republic) | 1 | 2013 | 1 | 0.110 |
Why?
|
| Vitamin D | 1 | 2015 | 260 | 0.110 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 585 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 1235 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2021 | 33737 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 2013 | 136 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 278 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2020 | 1546 | 0.100 |
Why?
|
| Curriculum | 1 | 2018 | 919 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 122 | 0.100 |
Why?
|
| Injections, Intramuscular | 1 | 2022 | 247 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2015 | 672 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2018 | 613 | 0.090 |
Why?
|
| Aeromonas hydrophila | 1 | 2011 | 5 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2020 | 1933 | 0.090 |
Why?
|
| Mexico | 2 | 2021 | 275 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2015 | 699 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 678 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 361 | 0.090 |
Why?
|
| Decision Making | 1 | 2018 | 1252 | 0.090 |
Why?
|
| Cross Infection | 1 | 2015 | 550 | 0.090 |
Why?
|
| Risk | 1 | 2014 | 1939 | 0.090 |
Why?
|
| Aminoglycosides | 1 | 2011 | 233 | 0.090 |
Why?
|
| Soft Tissue Infections | 1 | 2011 | 93 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2400 | 0.090 |
Why?
|
| Biopsy | 1 | 2017 | 3484 | 0.080 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 248 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 1655 | 0.080 |
Why?
|
| Salmonella enterica | 1 | 2009 | 12 | 0.080 |
Why?
|
| Salmonella typhi | 1 | 2009 | 21 | 0.080 |
Why?
|
| Mass Vaccination | 1 | 2009 | 19 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 2650 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 4831 | 0.080 |
Why?
|
| Pandemics | 2 | 2023 | 1610 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2015 | 801 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 430 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2011 | 510 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 437 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 8130 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 1302 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 3949 | 0.060 |
Why?
|
| United States | 3 | 2021 | 15861 | 0.060 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2008 | 593 | 0.060 |
Why?
|
| Prevalence | 1 | 2013 | 3404 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 2345 | 0.060 |
Why?
|
| Polysorbates | 1 | 2024 | 26 | 0.060 |
Why?
|
| Squalene | 1 | 2024 | 22 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 15218 | 0.060 |
Why?
|
| Vaccinia virus | 1 | 2014 | 85 | 0.060 |
Why?
|
| Time Factors | 2 | 2020 | 13006 | 0.060 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 641 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2014 | 95 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2018 | 1179 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2003 | 338 | 0.050 |
Why?
|
| China | 1 | 2024 | 636 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 6390 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 3187 | 0.050 |
Why?
|
| Singapore | 1 | 2021 | 32 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 76 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 241 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7783 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6256 | 0.050 |
Why?
|
| Hospitalization | 2 | 2020 | 2167 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 328 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 7044 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 1472 | 0.040 |
Why?
|
| Oseltamivir | 1 | 2019 | 29 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2023 | 313 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 75 | 0.040 |
Why?
|
| Aging | 2 | 2017 | 1534 | 0.040 |
Why?
|
| Minnesota | 1 | 2018 | 126 | 0.040 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 16 | 0.040 |
Why?
|
| Sterols | 1 | 2017 | 21 | 0.040 |
Why?
|
| Inositol Phosphates | 1 | 2017 | 26 | 0.040 |
Why?
|
| Oxygen | 1 | 2021 | 791 | 0.040 |
Why?
|
| Gram-Positive Bacteria | 1 | 2016 | 68 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2017 | 386 | 0.030 |
Why?
|
| Vaccination Refusal | 1 | 2016 | 17 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2016 | 107 | 0.030 |
Why?
|
| Risk Factors | 1 | 2013 | 17888 | 0.030 |
Why?
|
| Developed Countries | 1 | 2015 | 46 | 0.030 |
Why?
|
| Central Venous Catheters | 1 | 2016 | 100 | 0.030 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 64 | 0.030 |
Why?
|
| Georgia | 1 | 2015 | 53 | 0.030 |
Why?
|
| Candida | 1 | 2016 | 171 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2017 | 380 | 0.030 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2015 | 12 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 485 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Proteins | 1 | 2003 | 2043 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2017 | 425 | 0.030 |
Why?
|
| Zika Virus | 1 | 2016 | 150 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 417 | 0.030 |
Why?
|
| Zika Virus Infection | 1 | 2016 | 174 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 372 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 889 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 291 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2018 | 488 | 0.030 |
Why?
|
| Ethanol | 1 | 2015 | 272 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 504 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 329 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 680 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2015 | 143 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2015 | 594 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1267 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 2057 | 0.020 |
Why?
|
| Fresh Water | 1 | 2011 | 21 | 0.020 |
Why?
|
| Tobramycin | 1 | 2011 | 25 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1099 | 0.020 |
Why?
|
| Amikacin | 1 | 2011 | 37 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3045 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1097 | 0.020 |
Why?
|
| Cephalosporins | 1 | 2011 | 174 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 1552 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5149 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 4492 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2003 | 107 | 0.010 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2003 | 85 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2016 | 39890 | 0.010 |
Why?
|
| Thermodynamics | 1 | 2003 | 194 | 0.010 |
Why?
|
| Dimerization | 1 | 2003 | 311 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 5923 | 0.010 |
Why?
|